Skip to content Skip to footer
Viewpoints_Jason Lerner

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots:  Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies  Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…

Read more

Key Biosimilars Events of October 2024

Key Biosimilars Events of October 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Dong-A ST’s Imuldosa…

Read more

Viewpoints_Fred Aslan

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots:  Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases  Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…

Read more

Prescription Drugs Top 20 2024

Top 20 Prescription Drugs of 2024

Shots: Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…

Read more

Viewpoints_Adityo Prakash

AI in Drug Discovery: Adityo Prakash from Verseon in an Illuminating Dialogue Exchange with PharmaShots

Shots:  AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs  Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models  Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…

Read more

Viewpoints_Mina Makar

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots:  Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032.  The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD.  In collaboration with…

Read more